首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1639244

融合活體組織切片市場機會、成長促進因素、產業趨勢分析和 2025 年至 2034 年預測

Fusion Biopsy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 to 2034

出版日期: 2024年11月21日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024 年全球融合活體組織切片市場價值為 8.291 億美元，預計 2025 年至 2034 年將以 9.9% 的年複合成長率(CAGR) 成長。對早期發現、支持性政府政策和報銷計劃的認知。

融合活體組織切片結合了 MRI 和超音波成像，透過針對特定區域進行活體組織切片來提高診斷精度。這項先進技術在檢測前列腺癌方面發揮著至關重要的作用，前列腺癌在老年男性中非常普遍。傳統的活體組織切片方法通常缺乏早期診斷所需的準確性，但融合活體組織切片透過提供清晰、即時的影像來指導活體組織切片過程，從而克服了這一限制。此方法的精確度對於確保準確診斷、減少假陰性和改善前列腺癌的治療至關重要，特別是對於接受主動監測的患者。

市場分為兩大類：設備和配件。包括MRI 超音波融合系統在內的設備細分市場在2024 年以7.031 億美元的收入引領市場。精確指導活體組織切片程序的能力。隨著醫療機構越來越注重高品質的診斷工具，對融合活體組織切片設備的需求持續成長。

市場範圍
開始年份	2024年
預測年份	2025-2034
起始值	8.291 億美元
預測值	21億美元
複合年成長率	9.9%

市場的手術部分分為經直腸和經會陰手術。經直腸入路在 2024 年創造了 6.776 億美元的收入，預計 2025 年至 2034 年間將以 9.6% 的複合年成長率成長。

融合活體組織切片主要用於前列腺癌診斷，但也可用於腎臟癌和其他領域。由於檢出率的提高以及對早期篩檢和準確診斷的日益重視，前列腺癌診斷領域在 2024 年產生了最高的收入。這項需求進一步受到旨在鼓勵早期發現的提高認知活動的推動，從而改善生存結果。

醫院是融合活體組織切片技術的主要最終用戶，其先進的基礎設施和訓練有素的醫務人員支持其市場佔有率。這些設施配備了必要的成像技術來進行精確的融合活體組織切片，使其成為這些手術的首選設置。

北美市場是主要的成長動力，對全球市場收入做出了重大貢獻。該地區先進的醫療基礎設施，加上前列腺癌的高發病率，支持擴大採用融合活體組織切片技術作為標準診斷工具。

產業生態系統分析
產業影響力
- 成長動力
  - 攝護腺癌盛行率增加
  - 成像技術的進步
  - 提高認知和篩檢計劃
  - 政府支持政策和報銷
- 產業陷阱與挑戰
  - 設備和流程成本高
成長潛力分析
監管環境
報銷場景
技術景觀
未來市場趨勢
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2034 年

主要趨勢
裝置
配件

第 6 章：市場估計與預測：按程序類型，2021 - 2034 年

主要趨勢
經直腸
經會陰

第 7 章：市場估計與預測：按應用分類，2021 - 2034 年

主要趨勢
前列腺癌診斷
腎臟癌診斷
其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2034 年

主要趨勢
醫院
診斷影像中心
門診手術中心
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 10 章：公司簡介

Canon Medical Systems
CIVCO Medical Solutions
Eigen Health
Esaote SpA
Exact imaging
Focal Healthcare
GE HealthCare
Koelis
Koninklijke Philips NV
MedCom
Merit Medical Systems
Siemens Healthineers

簡介目錄

Product Code: 12341

The Global Fusion Biopsy Market was valued at USD 829.1 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2025 to 2034. The market's rapid expansion is driven by the increasing prevalence of prostate cancer, growing awareness of early detection, and supportive government policies and reimbursement programs.

Fusion biopsy combines MRI and ultrasound imaging to enhance diagnostic precision by targeting specific areas for biopsy. This advanced technique plays a crucial role in detecting prostate cancer, which is highly prevalent among older men. Conventional biopsy methods often lack the accuracy needed for early diagnosis, but fusion biopsy overcomes this limitation by providing clear, real-time images that guide the biopsy procedure. The method's precision is crucial for ensuring accurate diagnoses, reducing false negatives, and improving the management of prostate cancer, especially for patients undergoing active surveillance.

The market is divided into two main categories: devices and accessories. The devices segment, which includes MRI-ultrasound fusion systems, led the market with a revenue of USD 703.1 million in 2024. These systems are essential for improving diagnostic accuracy in prostate cancer detection, offering clinicians enhanced visibility and the ability to precisely guide biopsy procedures. As healthcare facilities increasingly focus on high-quality diagnostic tools, the demand for fusion biopsy devices continues to rise.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$829.1 Million
Forecast Value	$2.1 Billion
CAGR	9.9%

The procedure segment of the market is categorized into transrectal and transperineal approaches. The transrectal approach generated USD 677.6 million in 2024 and is expected to grow at a 9.6% CAGR between 2025 and 2034. This method is widely preferred for its ability to target specific lesions within the prostate with accuracy, thanks to its established procedural framework and the familiarity of healthcare providers with its use.

Fusion biopsy is primarily used for prostate cancer diagnosis, although it also has applications in kidney cancer and other areas. The prostate cancer diagnosis segment generated the highest revenue in 2024, benefiting from improved detection rates and the growing emphasis on early screening and accurate diagnosis. This demand is further driven by heightened awareness campaigns aimed at encouraging early detection, which improves survival outcomes.

Hospitals are the dominant end users of fusion biopsy technology, with a market share supported by their advanced infrastructure and highly trained medical staff. These facilities are equipped with the necessary imaging technologies to perform accurate fusion biopsies, making them the preferred setting for these procedures.

The North America market is a key growth driver, contributing significantly to the global market revenue. The region's advanced healthcare infrastructure, coupled with high prostate cancer incidence rates, supports the growing adoption of fusion biopsy techniques as a standard diagnostic tool.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of prostate cancer
  - 3.2.1.2 Advancements in imaging technology
  - 3.2.1.3 Growing awareness and screening programs
  - 3.2.1.4 Supportive government policies and reimbursement
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of equipment and procedures
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technology landscape
3.7 Future market trends
3.8 Gap analysis
3.9 Porter's analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Devices
5.3 Accessories

Chapter 6 Market Estimates and Forecast, By Procedure Type, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Transrectal
6.3 Transperineal

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Prostate cancer diagnosis
7.3 Kidney cancer diagnosis
7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostic imaging centers
8.4 Ambulatory surgical centers
8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE